Eton Pharmaceuticals Submits IND for Phase 2 Mecasermin Study
Eton Pharmaceuticals submitted an investigational new drug application to the FDA for a Phase 2 study of mecasermin/IGF-1. Dosing is planned for Q1 2027.
Related stories
Marvell acquires Lumentum
M impact | EQUITY | Nov 02, 2026, 01:44 PM UTC
Infineon shares rise 3.6%
M impact | EQUITY | Nov 02, 2026, 01:43 PM UTC
Out West Restaurant Group Files for Chapter 11 Bankruptcy
The filing covers 61 Outback Steakhouse locations.
M impact | EQUITY | Nov 02, 2026, 01:42 PM UTC
Birchtech Files Brief Supporting $78 Million Patent Judgment
Birchtech filed a brief in the Federal Circuit supporting the $78 million patent infringement judgment against Cert defendants.
L impact | EQUITY | Nov 02, 2026, 01:41 PM UTC
Oracle Seeks Funds Through Bond and Share Issues
Oracle is seeking funds through bond and share offerings, Reuters reported.
M impact | EQUITY | Nov 02, 2026, 01:41 PM UTC
Marvell agrees to acquire Lumentum in an all-stock deal
Marvell agreed to acquire Lumentum through a stock-for-stock exchange.
M impact | EQUITY | Nov 02, 2026, 01:41 PM UTC